Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
20 Luglio 2022 - 12:00PM
Business Wire
New data emphasizes the utility of the
VeriStrat® Proteomic Test to identify patients likely to benefit
from Immune Checkpoint Inhibitors
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, announced today
that Young Kwang Chae, MD, MPH, MBA, Associate Professor of
Medicine (Hematology and Oncology) Feinberg School of Medicine,
Northwestern University will present the results of a retrospective
analysis at the IASLC 2022 World Conference on Lung Cancer
hosted by the International Association for the Study of Lung
Cancer (#WCLC2022) on August 8, 2022 in Vienna,
Austria.
The analysis from Northwestern University included patients with
advanced-stage non-small cell lung cancer (NSCLC) who received
Immune Checkpoint Inhibitors (ICIs) as monotherapy or in
combination with chemotherapy with PD-L1 <50%. Patients
underwent Biodesix’s blood-based VeriStrat proteomic testing from
2016 to 2021. This data demonstrated that the VeriStrat test result
was predictive of Progression Free Survival (PFS) and Overall
Survival (OS) in patients with NSCLC with low or negative PD-L1
treated with ICIs. Patients whose VeriStrat status results were
VeriStrat Good (VS-G) had significantly greater PFS and OS as
compared to the patients whose status was VeriStrat Poor
(VS-P).
The VeriStrat test is a blood-based test utilizing a proteomic
signature identified using MALDI-ToF mass spectrometry coupled with
machine learning. Results from this test have been shown to have
predictive and prognostic utility in different stages, histologies,
and treatment types for patients with NSCLC. More recently, the
VeriStrat test has also shown to be predictive of outcomes in
patients receiving ICI treatment. Data in this study further
enhances the existing data by showing the role of this blood-based
test among lung cancer patients with low PD-L1 expression.
“The overall efficacy of ICIs in patients with low PD-L1
expression needs further investigation. Immune-checkpoint
inhibitors targeting PD-1 or PD-L1 have already substantially
improved the outcomes of patients with many types of cancer,
although only 20-40% of patients derive benefit from these new
therapies. A lower percentage of patients with low PD-L1 expression
respond to checkpoint inhibitors, however those who do respond
derive significant benefit,” said Young Kwang Chae, MD, MPH, MBA.
“We need additional diagnostic tests, beyond PD-L1 testing alone,
to better identify those likely to respond to checkpoint inhibition
ahead of treatment initiation. This data shows potential for the
VeriStrat test to play a role in this decision.”
Details for the e-poster presentations are as
follows:
Title: The Role of Serum Proteomic Signature in
Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer
Receiving Immune Checkpoint Inhibitor.
Authors: Leeseul Kim, Sung Mi Yoon, Joo Hee Park, Young
Kwang Chae – Northwestern Feinberg School of Medicine, Chicago,
IL
Abstract Number: P.2.12-04
Session Category: Tumor Biology and Biomarkers - Immune
Biology & Immunotherapy
Session Date and Time: August 8, 2022, 5:15-7:15 pm
CEST
Poster will be archived on the Biodesix website at
www.biodesix.com
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix is the first
company to offer eight non-invasive tests for patients with lung
diseases. The blood based Nodify Lung® nodule risk assessment
testing strategy, consisting of the Nodify XL2® and the Nodify CDT®
tests, evaluates the risk of malignancy in incidental pulmonary
nodules, enabling physicians to better triage patients to the most
appropriate course of action. The blood based IQLung™ strategy for
lung cancer patients integrates the GeneStrat® ddPCR™ test, the
GeneStrat NGS™ test and the VeriStrat® test to support treatment
decisions across all stages of lung cancer with results in an
unprecedented 36-72 hours, expediting time to treatment. Biodesix
also leverages the proprietary and advanced Diagnostic Cortex® AI
(Artificial Intelligence) platform, to collaborate with many of the
world’s leading biotechnology and pharmaceutical companies to solve
complex diagnostic challenges in lung disease. Biodesix launched
the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and
the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™
Neutralization Test Kit, GenScript, Inc,) in response to the global
pandemic and virus that impacts the lung and causes COVID-19. For
more information about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, it is possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220720005310/en/
Media: Bobbi Coffin bobbi.coffin@biodesix.com (303) 892-3203
Investors: Chris Brinzey chris.brinzey@westwicke.com (339)
970-2843
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Lug 2023 a Lug 2024